Cell and gene therapies are producing remarkable clinical results but, for many, the delivery mechanism remains a fundamental constraint. In subretinal gene therapy, skilled surgeons and a freehand needle are the standard of care. This creates two compounding problems: variability across surgeons and sites that undermines clinical trials, and a dependency on scarce surgical expertise that presents a serious commercial barrier.

This talk examines the trade-offs for local drug delivery and presents a sub-retinal delivery device as a path toward more consistent, scalable administration of subretinal gene therapies.

Nathan Wilkinson

Development Lead – Drug Delivery 

TTP plc